cas 6327-98-6|| where to buy 3-methyl-2-(methylthio)pyrimidin-4(3H)-one

Produktname:3-methyl-2-(methylthio)pyrimidin-4(3H)-one

IUPAC Name:3-methyl-2-(methylsulfanyl)-3,4-dihydropyrimidin-4-one

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM164879-1g	1-2 Weeks	ŵǑŵ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6327-98-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:6327-98-6; Molekulare Formel:C6H8N2OS; Schmelzpunkt:-; SMILES-Code:O=C1N(C)C(SC)=NC=C1; Dichte:

: Katalognummer:CM164879; Molekulargewicht:156.2; Siedepunkt:; Mdl-Nr.:MFCD00154768; Lagerung:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Vimseltinib; Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.